| 27th week of 2012 patent applcation highlights part 51 |
| Patent application number | Title | Published |
|---|
| 20120172278 | STAIN PRETREATMENT AGENT - The present invention relates to a stain pretreatment agent containing a mixture of a short-chain and a long-chain polyethylene glycol and to the use thereof, and to a cleaning pen containing said stain pretreatment agent. | 2012-07-05 |
| 20120172279 | Liquid Cleaning Compositions Containing Sulfonated Estolides and Alkyl Ester Sulfonates - Liquid cleaning compositions are described that comprise sulfo-estolide (SE) salts, particular sodium, lithium or ammonium salts of sulfo-estolides, and alkyl ester sulfonates. The liquid cleaning compositions are clear, stable and substantially free of precipitates due to the use of sodium, lithium or ammonium salts of sulfo-estolide rather than a potassium sulfo-estolide salt in the composition. The liquid cleaning compositions also have a total combined amount of saturated C16 and C18 fatty acids of less than about 5% by weight to prevent the formation of precipitates in the composition. | 2012-07-05 |
| 20120172280 | Protease Variants - The present invention relates to protease variants. The present invention also relates to polynucleotides encoding the variant protease variants and to nucleic acid constructs, vectors, and host cells comprising the polynucleotides, and methods of using the variant enzymes, such as, in laundry and detergent compositions. | 2012-07-05 |
| 20120172281 | DETERGENT COMPOSITIONS COMPRISING MICROBIALLY PRODUCED FATTY ALCOHOLS AND DERIVATIVES THEREOF - Disclosed herein are detergent compositions comprising a microbially produced fatty alcohol or fatty alcohol derivative thereof. Further disclosed are cleaning compositions and personal care compositions comprising a microbially produced fatty alcohol or fatty alcohol derivative thereof. Methods of using the foregoing are also disclosed. | 2012-07-05 |
| 20120172282 | Isosorbide Glyceryl Ether Derivatives And Their Use In Household Applications - Disclosed are isosorbide glyceryl ether derivatives according to the following general formula (I), wherein R or R′ represent a hydrogen atom, or an alkyl or an acyl group with 6 to 22 C-atoms, and n and m represent independent from each other zero, or a number from 1 to 4, and the use thereof in cleansers or detergents or personal care applications. | 2012-07-05 |
| 20120172283 | METHODS AND COMPOSITIONS FOR TARGETED DRUG DELIVERY - Disclosed are Drug Delivery Molecules (DDMs) which both facilitate functional imaging, as by PET, MRI or SPECT, and create a biological effect and methods of their use. These DDMs which are variously designed to target specific receptors, internalized and then function biologically, as for purposes of cell destruction or therapy. | 2012-07-05 |
| 20120172284 | ISOZYME-SPECIFIC ANTAGONISTS OF PROTEIN KINASE C - A method of changing or otherwise converting the biological activity of a PKC peptide agonist to a peptide antagonist is described. The method involves substituting one or more amino acid residues so as to effect a change in charge in the peptide and/or to otherwise make the sequence similar to a sequence derived from the PKC binding site on the RACK protein for the respective PKC enzyme. Methods of inhibiting the activity of a PKC enzyme, and various peptide antagonists of εPKC are also disclosed. | 2012-07-05 |
| 20120172285 | METHODS AND COMPOSITIONS FOR SPECIFIC MODULATION OF MCL-1 - A series of stapled BCL-2 family peptide helices were identified as able to target the survival protein MCL-I with high affinity and a subset with unprecedented selectivity. Agents and methods for selective pharmacologic neutralization of MCL-I are provided for drug discovery and therapeutic uses, including use in overcoming the apoptotic resistance of cancer and other diseases associated with impaired cell death. | 2012-07-05 |
| 20120172286 | THERAPEUTIC USE FOR ALPHA1 PROTEINASE INHIBITOR IN HEMATOPOIESIS - A previously unrecognized fundamental property of α | 2012-07-05 |
| 20120172287 | Polypeptide Having Antibacterial Activity and Angiogenesis-Inducing Activity and Wound-Healing Drug Containing Said Polypeptide - A novel polypeptide which has an excellent angiogenesis-inducing activity and an excellent antibacterial activity, and a novel angiogenesis-inducing agent which contains the polypeptide as an effective ingredient or a novel agent for treating a wound(s) which contains the polypeptide as an effective ingredient are disclosed. The polypeptide of the present invention is a polypeptide whose amino acid sequence is shown in any one of SEQ ID NOs:1 to 6, 8 and 10. The angiogenesis-inducing agent which contains the polypeptide of the present invention as an effective ingredient is useful for the prevention, amelioration or treatment of a disease such as a burns, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliteran. | 2012-07-05 |
| 20120172288 | USE OF NUTRITIONAL COMPOSITIONS INCLUDING LACTOFERRIN IN SUPPORTING RESISTANCE TO DISEASES AND CONDITIONS - The present disclosure relates to the use of nutritional compositions including lactoferrin produced by a non-human source in supporting resistance to diseases or conditions caused by bacterial and viral pathogens. | 2012-07-05 |
| 20120172289 | MULTIFUNCTIONAL GLYCOPEPTIDE ANTIBIOTIC DERIVATIVES FOR FLUORESCENT IMAGING AND PHOTOACTIVE ANTIMICROBIAL THERAPY - The present invention relates to a compound of formula (I) and compositions thereof, methods of their production as well as methods for treating bacterial infection. | 2012-07-05 |
| 20120172290 | Anti-Viral Compounds - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 2012-07-05 |
| 20120172291 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to novel fluorinated macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. | 2012-07-05 |
| 20120172292 | METHOD FOR PROTECTION OF ANTIMICROBIAL AND ANTICANCER DRUGS FROM INACTIVATION BY NITRIC OXIDE - This invention discloses a method for enhancing the efficacy of antimicrobial, anti-protozoa and anti-cancer treatments by co-administering an inhibitor of endogenous NO production and/or NO scavenger. | 2012-07-05 |
| 20120172293 | PEPTIDE AND USE THEREOF - The present invention aims to provide a peptide having a superior Y2 receptor agonist action and useful as an agent for the prophylaxis or treatment of obesity and the like. | 2012-07-05 |
| 20120172294 | TREATMENT OF DISEASES - The invention provides (i) a method of treating metabolic syndrome in an animal, (ii) a method of suppressing the appetite of an animal, (iii) a method of treating obesity in an animal, (iv) a method of reducing the weight of an animal in need thereof, (v) a method of reducing a blood lipid level in an animal in need thereof, (vi) a method of treating non-alcoholic steatohepatitis in an animal, and (vii) a method of inhibiting adipogenesis. The methods comprise administering an effective amount of an active ingredient, wherein the active ingredient comprises a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal. The invention also provides a kit comprising a container holding a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them; and instructions for administration. The diketopiperazines have the formula given in the application. | 2012-07-05 |
| 20120172295 | GIP RECEPTOR-ACTIVE GLUCAGON COMPOUNDS - Glucagon peptides with increased GIP activity are provided, optionally with GLP-I and/or glucagon activity. In some embodiments, C-terminally extended glucagon peptides comprising an amino acid sequence substantially similar to native glucagon are provided herein. | 2012-07-05 |
| 20120172296 | WATER-SOLUBLE AIE LUMINOGEN FOR MONITORING AND RETARDATION OF AMYLOID FIBRILLATION OF INSULIN - The presently described subject matter is directed to a water-soluble conjugated polyene compound and the derivatives thereof that exhibit aggregation induced emission, as well as any water dispersible, fluorescent, polymeric microparticles, nanoparticles, and/or pharmaceutical composition comprising the water-soluble conjugated polyene compound and/or the derivatives thereof. Also provided are methods of making and using the compound, derivatives and particles of the presently described subject matter. The presently described water-soluble conjugated polyene compound are useful as bioprobes for the detection of biomacromolecules, in the manufacture of sensors, in monitoring and retarding formation of amyloid protein fibril in vitro and in vivo, and in developing anti-cancer drugs. | 2012-07-05 |
| 20120172297 | SYNTHETIC HUMAN GENES AND POLYPEPTIDES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES - Synthetic human target autoantigen genes comprising sequences coding for at least two immunogenic epitopic clusters (hereinafter IEC) of autoantigen(s) related to a specific autoimmune disease, wherein said at least two IECs may be derived from a sole autoantigen or from at least two different autoantigens related to said autoimmune disease, and polypeptides encoded thereby, can be used for the treatment and the diagnosis of autoimmune diseases such as multiple sclerosis (MS), insulin-dependent diabetes mellitus (IDDM), rheumatoid arthritis (RA), myasthenia gravis (MG) and uveitis. | 2012-07-05 |
| 20120172298 | GLP-1 AND FGF21 COMBINATIONS FOR TREATMENT OF DIABETES TYPE 2 - The invention relates to the use of a Fibroblast Growth Factor 21 (FGF21) compound and a Glucagon-Like Peptide 1 (GLP-1) compound in combination for the preparation of a medicament for the treatment of diabetes, more in particular type 2 diabetes, as well as pharmaceutical compositions comprising certain FGF21 and GLP-1 compounds in combination, together with a pharmaceutically acceptable carrier. The combination has a significant effect on parameters of relevance for diabetes type 2, viz. on the viability of beta cells ex vivo in the presence of free fatty acids, on caspase activity of beta cells ex vivo (a measure of cell apoptosis), and a blood glucose lowering effect on db/db mice in vivo. | 2012-07-05 |
| 20120172299 | PURIFICATION OF ERYTHROPOIETIN - In the present invention a method for purifying erythropoietin comprising at least one chromatography step using a stationary phase containing hydroxyapatite is reported. The method comprises the following steps i) the erythropoietin in a solution containing Calcium-ions is brought into contact with a stationary phase containing hydroxyapatite equilibrated with a solution containing Calcium-ions and namely under conditions under which the erythropoietin binds to the stationary phase containing hydroxyapatite, ii) a solution is passed over the stationary phase containing hydroxyapatite from i) which contains less Calcium-ions than the previous solution and the erythropoietin is not detached from stationary phase containing hydroxyapatite, and iii) a further solution which contains less than 0.5 mM Calcium-ions is passed over the stationary phase containing hydroxyapatite from ii) whereby the erythropoietin is detached from the stationary phase containing hydroxyapatite. | 2012-07-05 |
| 20120172300 | REMODELING AND GLYCOPEGYLATION OF FIBROBLAST GROWTH FACTOR (FGF) - The present invention relates to mutants of Fibroblast Growth Factor (FGF), particularly FGF-20 and FGF-21, which contain newly introduced N-linked or O-linked glycosylation site(s). The polynucleotide coding sequences for the mutants, expression cassettes comprising the coding sequences, cells expressing the mutants, and methods for producing the mutants are also disclosed. Further disclosed are pharmaceutical compositions comprising the mutants and method for using the mutants. | 2012-07-05 |
| 20120172301 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANGIOTENSIN-(1-9), DERIVATIVES THEREOF, OR A VECTOR EXPRESSING ACE2, USEFUL FOR TREATING CARDIOVASCULAR, PULMONARY, CEREBRAL, AND/OR RENAL REMODELING - The present invention relates to a pharmaceutical composition comprising an effective amount of angiotensin-(1-9) or derivatives thereof, and at least one pharmaceutical acceptable carrier, excipient, stabilizer, diluent, and/or adjuvant. Additionally, the present invention describes the use of the pharmaceutical composition and the angiotensin-(1-9) peptide or peptides derived thereof which are biological or chemical analogous for the manufacture of medicaments useful for preventing, reverting, inhibiting, and/or reducing cardiovascular, pulmonary, cerebral, or renal remodeling. Additionally, this invention also comprises a method for preventing, reverting, inhibiting, and/or reducing cardiovascular, pulmonary, cerebral, or renal remodeling comprising elevating blood and/or tissue concentration of angiotensin-(1-9) or derivatives thereof peptide via a pharmaceutical composition that contains a vector expressing ACE2, enzyme responsible for the endogenous production of angiotensin-(1-9). These vectors correspond to adenovirus, retrovirus, lentivirus, or adeno-associated viruses containing the gene that encodes ACE2. This invention allows to administer angiotensin-(1-9) or derivatives thereof via oral route, injections, pump continuous infusion, or elevate its levels in the organism through treatment with angiotensin I-converting enzyme inhibitors, angiotensin II receptor antagonists (ARA II), with Rho kinase inhibitors, with L-calcium channel antagonists, and/or with diuretics. | 2012-07-05 |
| 20120172302 | COMPOSITION FOR THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA - The present disclosure is directed to compositions and kits comprising degarelix or a pharmaceutically acceptable salt thereof for the treatment of benign prostate hyperplasia (BPH), methods for treating BPH, and methods for preparing compositions of degarelix or a pharmaceutically acceptable salt thereof. | 2012-07-05 |
| 20120172303 | Growth Hormones with Prolonged In-Vivo Efficacy - The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin. | 2012-07-05 |
| 20120172304 | INTRANASAL CARBETOCIN FORMULATIONS AND METHODS FOR THE TREATMENT OF AUTISM - Methods and compositions containing oxytocin or an oxytocin analog, such as carbetocin, are provided for the prevention and treatment of autism spectrum disorders, related disorders and symptoms of such disorders. The methods and compositions of this disclosure are effective in the treatment of social withdrawal, eye contact avoidance, repetitive behaviors, anxiety, attention deficit, hyperactivity, depression, loss of speech, verbal communication difficulties, aversion to touch, visual difficulties, comprehension difficulties, and sound and light sensitivity. Additional compositions and methods are provided which employ oxytocin or an oxytocin analog in combination with a secondary or adjunctive therapeutic agent to yield more effective treatment tools against autism spectrum disorders and related disorders. | 2012-07-05 |
| 20120172305 | RETRO-INVERSO PEPTIDES DERIVED FROM INTERLEUKIN-6 - This invention provides methods of treatment using retro-inverso peptides derived from interleukin-6 (IL-6) having between 15 and about 40 amino acids, and including the sequence that is retro-inverso with respect to SEQ ID NO 1, i.e. wherein said peptide comprises the sequence D-Glu-D-Ala-D-Met-D-Lys-D-Pro-D-Leu-D-Asn-D-Leu-D-Asn-D-Asn-D-Glu-D-Ala-D-Leu-D-Ala-D-Glu. The peptides of the invention have the same activity as native IL-6 and also have neurotrophic activity. The peptides of the invention are also less susceptible to proteolytic degradation in vivo because of their D-amino acid linkage. | 2012-07-05 |
| 20120172306 | Use of HASF as a Protective Agent Against Ischemic Tissue Damage - A method of inducing a protective response against ischemic tissue damage is carried out by administering to subject a composition comprising an HASF polypeptide. The composition is administered prior to an ischemic event such as myocardial infarction to reduce tissue damage associated with such an event. | 2012-07-05 |
| 20120172307 | METHODS FOR REDUCING THE INCIDENCE OF OXIDATIVE STRESS USING HUMAN MILK OLIGOSACCHARIDES, VITAMIN C AND ANTI-INFLAMMATORY AGENTS - Disclosed are methods of reducing the incidence of oxidative stress in infants, toddlers, and children using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective at reducing inflammation and the incidence of inflammatory diseases. | 2012-07-05 |
| 20120172308 | Oligopeptides And Their Use In Cosmetics - The present invention relates to the cosmetic use of oligopeptides, cosmetic preparations which comprise such oligopeptides as well as certain oligopeptide derivatives themselves. | 2012-07-05 |
| 20120172309 | TRANSGLUTAMINASE-ACTIVATING PEPTIDE AND COSMETIC OR PHARMACEUTIAL COMPOSITION CONTAINING SAME - The present invention relates to a peptide of general formula (I): | 2012-07-05 |
| 20120172310 | Soluble Guanylyl Cyclase a1 and a-8r Peptide as Diagnostic Markers of and Therapeutic Targets for Prostate Cancer - The present invention provides materials and methods useful to treat various sGCα1-expressing cancers. Materials include peptides which interfere with sGCα1's pro-survival functions, thereby resulting in apoptosis of sGCα1-expressing cells. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits. | 2012-07-05 |
| 20120172311 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides biologically active crosslinked polypeptides with improved properties relative to their corresponding precursor polypeptides, having good cell penetration properties and reduced binding to human proteins. The invention additionally provides methods of identifying and making such improved polypeptides. | 2012-07-05 |
| 20120172312 | MUC-1 CYTOPLASMIC DOMAIN PEPTIDES AS INHIBITORS OF CANCER - The invention provides for peptides from the MUC1 cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, thereby preventing tumor cell growth, inducing tumor cell apoptosis and necrosis of tumor tissue in vivo. | 2012-07-05 |
| 20120172313 | TREATMENT OF PROLIFERATIVE DISEASES - The present invention relates to methods for preventing or treating proliferative diseases. In particular, the present invention relates to the use of compositions derived or derivable from plants, such as plant defensins, particularly in methods for the prevention or treatment of proliferative diseases such as cancer. The present invention also relates to associated uses, systems and kits. | 2012-07-05 |
| 20120172314 | Klotho Protein and Related Compounds for the Treatment and Diagnosis of Cancer - Disclosed is the use of a klotho protein or related compounds for the diagnosis and treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents or hormone-regulating agents. | 2012-07-05 |
| 20120172315 | Peptides Used for Treating Cancers and, in Particular, Chronic Lymphoid Leukaemia - The invention relates to the A1 peptide of the sequence RRKYGRDFLLRF, as well as to certain variants thereof, for treating cancers, in particular malignant hematopoietic diseases, and more particularly for treating chronic lymphoid leukaemia. | 2012-07-05 |
| 20120172316 | CLONING, YEAST EXPRESSION, PURIFICATION AND BIOLOGICAL ACTIVITY OF THE EXTENSION REGION OF THE SOYBEAN 7S GLOBULIN ALFA' SUBUNIT INVOLVED IN HEP G2 CELL CHOLESTEROL HOMEOSTASIS - A truncated form of α′ chain (eα′), the soybean 7S globulin, active in controlling the cholesterol and triglyceride homeostasis in in vitro and in vivo models, was cloned and expressed in the yeast | 2012-07-05 |
| 20120172317 | SILK FIBROIN HYDROGELS AND USES THEREOF - The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices. | 2012-07-05 |
| 20120172318 | PEPTIDES AND PEPTIDOMIMETICS USEFUL FOR INHIBITING THE ACTIVITY OF PROSTAGLANDIN F2alpha RECEPTOR - The invention relates to compositions which are useful for inhibiting prostaglandin F | 2012-07-05 |
| 20120172319 | METHODS FOR DECREASING THE INCIDENCE OF NECROTIZING ENTEROCOLITIS IN INFANTS, TODDLERS, OR CHILDREN USING HUMAN MILK OLIGOSACCHARIDES - Disclosed are methods of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective in reducing inflammation and the incidence of inflammatory diseases. | 2012-07-05 |
| 20120172320 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 - Pharmaceutical dosage forms useful for improving the cardiovascular and/or metabolic health of patients, particularly those suffering from type 2 diabetes, are disclosed, as well as methods of their manufacture. | 2012-07-05 |
| 20120172321 | HSP90 INHIBITORS - The invention relates to HSP90 inhibiting compounds consisting of the formula: | 2012-07-05 |
| 20120172322 | Methods of Controlling Insects - Methods of controlling insects include applying at least one spinosyn compound to a locus of a neonicotinoid-resistant insect, such as a strain of | 2012-07-05 |
| 20120172323 | METHODS FOR TREATING MALARIA, TUBERCULOSIS AND MAC DISEASES - Described herein are formulations and methods for treating diseases caused by infectious pathogens, including | 2012-07-05 |
| 20120172324 | COMPOSITIONS AND METHODS FOR REDUCING THE RISK OF AGENT-INDUCED LIVER TOXICITY - The present disclosure relates generally to a co-formulation or co-administration of acetaminophen with one or more chemicals that are metabolites or their derivatives in the methionine and glutathione biosynthesis pathways, for protection against acetaminophen-induced liver toxicity. The formulation may comprise acetaminophen and diet supplements such as S-methylmethionine (SMM). The present disclosure also encompasses methods of providing pain or fever relief with protection against acetaminophen-induced liver injury with the formulations described herein. Embodiments of the present disclosure also include co-formulation or co-administration of an agent and one or more other chemicals for reducing agent-induced liver toxicity via depletion of glutathione. | 2012-07-05 |
| 20120172325 | Methods and Compositions for the Treatment of Gastrointestinal Disorders - The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis employing. The methods and compositions employ guanosine 3′,5′-cyclic monophosphate pharmaceutically acceptable salt thereof. | 2012-07-05 |
| 20120172326 | Moisturizing Mixture, Cosmetic And/Or Pharmaceutical Compositions Containing The Moisturizing Mixture, Use Of The Moisturizing Mixture, And Cosmetic Method - The present invention refers to a moisturizing mixture for sensitive skins, atopic dermatitis and/or | 2012-07-05 |
| 20120172327 | NUTRITIONAL FORMULATIONS INCLUDING HUMAN MILK OLIGOSACCHARIDES AND ANTIOXIDANTS AND USES THEREOF - Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases. | 2012-07-05 |
| 20120172328 | HYALURONIC ACID-BASED GELS INCLUDING LIDOCAINE - Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided. | 2012-07-05 |
| 20120172329 | PHYTOCHEMICAL COMPOSITIONS INCLUDING XANTHONES FOR ANTI-INFLAMMATORY, ANTI-CYTOKINE STORM, AND OTHER USES - A composition (e.g., a phytochemical composition) including a predetermined concentration of xanthones, and in certain embodiments predetermined concentrations of both xanthones and sesamin. The composition facilitates at least one of decreasing pro-inflammatory cytokines, increasing anti-inflammatory cytokines, enhancing a connective tissue anti- degeneration effect, and inhibiting viral neuraminidase (e.g. neuraminidase of an influenza A virus). The composition can further decrease at least one of gene expression and release of pro-inflammatory cytokines. The phytochemical composition can increase at least one of gene expression and release of anti-inflammatory cytokines. The phytochemical composition provides at least one of an anti-inflammatory, an anti-viral (e.g., anti-influenza), and a connective tissue anti-degradation effect in a living organism. A use of xanthones for manufacturing phytochemical compositions that include predetermined concentrations of xanthones is also provided. A use of xanthones in combination with sesamin for manufacturing phytochemical compositions that include predetermined concentrations of both xanthones and sesamin is additionally provided. | 2012-07-05 |
| 20120172330 | HUMAN MILK OLIGOSACCHARIDES FOR MODULATING INFLAMMATION - Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases. | 2012-07-05 |
| 20120172331 | METHODS OF USING HUMAN MILK OLIGOSACCHARIDES FOR IMPROVING AIRWAY RESPIRATORY HEALTH - Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to preterm infants, term infants, toddlers, and children for improving airway defense mechanisms. | 2012-07-05 |
| 20120172332 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS - Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): | 2012-07-05 |
| 20120172333 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK - The present invention relates to pyrrolopyridone compounds of the formula (I), | 2012-07-05 |
| 20120172334 | CONTROLLED RELEASE PARTICLES AND METHOD FOR PRODUCING THE SAME - Controlled release particles are obtained by dissolving a hydrophobic antibiotic compound in a hydrophobic polymerizable vinyl monomer without the presence of a solvent, thereby preparing a hydrophobic solution, the hydrophobic antibiotic compound having a melting point of 100° C. or less, a polar term δp,compound of 2 to 8 [(J/cm | 2012-07-05 |
| 20120172335 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE - The present invention relates to novel benzimidazolone derivatives of the general formula (I) in which the substituents R | 2012-07-05 |
| 20120172336 | Fosfluconazole Derivatives, Synthesis, and Use in Long Acting Formulations - The invention relates to a compound of formula (1) and the salts, N-oxides, quaternary amines, and stereoisomers thereof, wherein R | 2012-07-05 |
| 20120172337 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES - The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents. | 2012-07-05 |
| 20120172338 | TOPICAL GEL FORMULATION COMPRISING ORGANOPHOSPHATE INSECTICIDE AND ITS PREPARATION THEREOF - The present invention provides a topical gel pharmaceutical formulation of insecticide suitable for treating an ectoparasite in a mammal, comprising: a) about 0.1-10% by weight of an insecticide; b) at least about 75% by weight of an organic solvent selected from the group consisting of a lower alkyl alcohol, a ketone, a glycol and a mixture thereof, wherein the organic solvent contains at least about 40% by weight of the lower alkyl alcohol; and c) at least one polymer selected from the group consisting of a cellulosic polymer, acrylates, methacrylates, and polyvinyl pyrrolidone. The present topical formulations encompass a non-flammable solvent for malathion effective in killing head lice. The present gel pharmaceutical formulation preferably contains malathion and optionally contains isopropyl myristate. The present invention further provides a process of preparing as well as a method of treating ectoparasites in a mammal using the same. | 2012-07-05 |
| 20120172339 | ANGIOGENIC RESORCINOL DERIVATIVES - Novel resorcinol derivatives and methods of preparation and use are presented. These compounds can stimulate angiogenesis as a biological function triggered by the activation of one cannabinoid receptor distinct from CB1 and CB2. Thus, these compounds are specific ligands for one cannabinoid receptor distinct from CB1 and CB2. The invented compounds, when administered in a therapeutically effective amount to an individual or animal, results in a sufficiently high level of that compound in the individual or animal to cause a physiological response. The physiological response may be useful to treat a number of physiological conditions. | 2012-07-05 |
| 20120172340 | Compositions and Methods for Selectively Activating Human Sirtuins - Methods for identifying selective activators of SIRT5 and/or SIRT1 and methods for using these selective activators in the modulation of SIRT5 and/or SIRT1 are provided. | 2012-07-05 |
| 20120172341 | COMPOSITIONS COMPRISING TRAMADOL AND CELECOXIB IN THE TREATMENT OF PAIN - The present invention relates to pharmaceutical compositions comprising tramadol and celecoxib and their uses as medicaments or analgesics, more particularly for the treatment of severe to moderate pain with an inflammation component. | 2012-07-05 |
| 20120172342 | Biotherapeutics For the Treatment of Infectious Diseases - An occlusive dressing made with an elastomeric gel and one or more active agents is described. The elastomeric gel contains a plasticizing oil phase and a block copolymer agent. Methods of preventing, treating, curing or mitigating an infectious disease and methods of making the dressings are also disclosed. | 2012-07-05 |
| 20120172343 | PHARMACEUTICAL COMPOSITION FOR EMERGENCY CONTRACEPTION - The invention relates to pharmaceutical compositions for emergency contraception, to the use of levonorgestrel in combination with COX inhibitors for the preparation of pharmaceutical compositions for the stated purpose, and to a method for preparing these pharmaceutical compositions. | 2012-07-05 |
| 20120172344 | INSULIN-PRODUCING CELL INDUCER, GLUCOSE INTAKE ENHANCER, AND THERAPEUTIC AGENT FOR DIABETES OR DIABETES COMPLICATIONS - Provided is an insulin-producing cell inducer, an enhancer for glucose intake of muscles, and a therapeutic agent for diabetes or diabetes complications, wherein an active ingredient of those provided is an estrogenic compound such as estrogen and estradiol. With the present invention, functions of insulin-producing cells can be recovered since the insulin-producing cells are induced in pancreatic ducts, and blood glucose level can be immediately lowered since glucose in the blood can be effectively taken up by muscles; therefore, diabetes and diabetes complications can be prevented or treated. | 2012-07-05 |
| 20120172345 | HETEROARYLS AND USES THEREOF - This invention provides compounds of formula IA-i-a or IB-i-a and subsets thereof: | 2012-07-05 |
| 20120172346 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS - The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease. | 2012-07-05 |
| 20120172347 | 8-OXODIHYDROPURINE DERIVATIVE - The present invention provides a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof (wherein W represents a hydrogen atom, a halogen atom, or the others; A represents an alkyl group optionally substituted by aryl group or the others, an aryl group, or the others; and one of X and Y represents a di-substituted alkylaminocarbonyl group, or the others, and the other represents a hydrogen atom, an alkyl group, an alkylcarbonyl group, or the others); a medicament or a pharmaceutical composition for treatment or prophylaxis of FAAH-related diseases such as depression, anxiety disorder or pains, comprising the compound or the like as an active ingredient; a use of the compound or the like; and a method for treatment or prophylaxis using the compound or the like. | 2012-07-05 |
| 20120172348 | STEROL DERIVATIVE - The present invention provides a sterol derivative or a pharmaceutically acceptable salt thereof having an activity to promote proliferation of neural stem cells. Namely, the present invention provides a sterol derivative represented by the general formula (I) (wherein Y represents optionally substituted lower alkyl or the like; X | 2012-07-05 |
| 20120172349 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS - Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer. | 2012-07-05 |
| 20120172350 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF - Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, including, e.g., neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as, e.g., histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical compositions containing the compounds and their methods of use are also provided herein. | 2012-07-05 |
| 20120172351 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF - A compound represented by the formula (I): wherein each symbol is as defined in the specification, and a salt thereof have a GPR40 receptor activation action and is useful as an insulin secretagogue or a prophylactic or therapeutic drug for diabetes and the like. | 2012-07-05 |
| 20120172352 | PYRAZOLINE DIONE DERIVATIVES AS NADPH OXIDASE INHIBITORS - The present invention is related to pyrazoline dione derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase). | 2012-07-05 |
| 20120172353 | 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL COMPOUNDS AND THEIR MEDICAL USE - This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. | 2012-07-05 |
| 20120172354 | Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines - The present invention relates to N-phenyl-1-(4-pyridinyl)-1H-pyrazol-3-amine derivatives and pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, according to formula (I) | 2012-07-05 |
| 20120172355 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP - This invention provides a compound of the formula (I): | 2012-07-05 |
| 20120172356 | SERUM BIOMARKERS FOR CHAGAS DISEASE - The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Chagas disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as infected with Chagas disease or non-infected. The biomarkers can be detected by SELDI mass spectrometry. | 2012-07-05 |
| 20120172357 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 - This invention relates to novel compounds of the Formula (I), dependent compounds of Formula (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (II-G), (II-H), (III), (III-A), (III-B), (III-C), (IV), (IV-A), (IV-B), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell. | 2012-07-05 |
| 20120172358 | GPCR Agonists - Compounds of formula (I): | 2012-07-05 |
| 20120172359 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders - The invention relates to novel heterocyclic compounds of the formula | 2012-07-05 |
| 20120172360 | NOVEL 1H-PYRIMIDIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS INHIBITORS OF AKT (PKB) PHOSPHORYLATION - The invention relates to the novel products of formula (I): | 2012-07-05 |
| 20120172361 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS - Compounds of the formula (I) and formula (II) and pharmaceutically acceptable salts thereof. | 2012-07-05 |
| 20120172362 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS - Provided are an agent for the treatment and/or prophylaxis of an anxiety disorder comprising, as an active ingredient, a thiazole derivative represented by the formula (I) wherein R | 2012-07-05 |
| 20120172363 | Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers - The present invention relates to a method for slowing the development of mammalian organ, tissue and cellular damage and death by using a persistent sodium current blocker (or a pharmaceutically acceptable salt or derivative thereof). The present invention further relates to a method for preventing damage and death in mammalian organs, tissues and cells or reducing the extent of damage and death in mammalian organs, tissues and cells. In particular the invention relates to a method for the treatment, amelioration or prevention of non-neuronal and non-myocardial cell or tissue damage or death and for reducing the pain associated with non-neuronal and non-myocardial cell or tissue damage. | 2012-07-05 |
| 20120172364 | RATE-CONTROLLED PARTICLES - Rate-controlled particles, comprising compounds of the formula | 2012-07-05 |
| 20120172365 | USE OF PHOSPHORDIESTERASE INHIBITORS IN THE TREATMENT OF PROSTATIC DISEASES - The present invention pertains to the use of inhibitors of phosphodiesterase I, IV and V for the prophylaxis and treatment of prostatic diseases, in particular the use of
| 2012-07-05 |
| 20120172366 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS - The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: | 2012-07-05 |
| 20120172367 | MACROCYCLIC INTEGRASE INHIBITORS - Compound having formula (I), wherein —W is NH—, —N(CH | 2012-07-05 |
| 20120172368 | Bis-Benzimidazole Derivatives - Inhibitors of HCV replication of formula I | 2012-07-05 |
| 20120172369 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE - The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (DGAT) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below: | 2012-07-05 |
| 20120172370 | PREPARATION OF CRYSTALLINE FORMS OF DIHYDROPYRAZOLOPYRIMIDINONE - The instant invention relates to crystalline forms of MK-1775, an inhibitor of Weel kinase. Specifically, the instant invention relates to hemihydrates of MK-1775. | 2012-07-05 |
| 20120172371 | FLUOROQUINOLONE DERIVATIVES OR SULFONAMIDE MOIETY-CONTAINING COMPOUNDS AS INHIBITORS OF TYROSYL-DNAPHOSPHODIESTERASE (TDP1) - A method for treating cancer in a subject, comprising administering to a subject having cancer a therapeutically effective amount of (i) a fluoroquinolone derivative that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity or (ii) a sulfonamide moiety-containing compound that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity, thereby treating the cancer in the subject. In certain embodiments, the fluoroquinolone derivative or sulfonamide moiety-containing compound is co-administered with a topoisomerase I (TopI) inhibitor. | 2012-07-05 |
| 20120172372 | Ureas and Their Use in the Treatment of Heart Failure - Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 2012-07-05 |
| 20120172373 | METHOD OF TREATING COGNITIVE IMPAIRMENTS AND SCHIZOPHRENIAS - The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT | 2012-07-05 |
| 20120172374 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME - Compounds represented by the formula (I) or pharmaceutically acceptable salts thereof: | 2012-07-05 |
| 20120172375 | COMPOUNDS AND METHODS OF PROMOTING OLIGODENDROCYTE PRECURSOR DIFFERENTIATION - A method of promoting the differentiation of an oligodendrocyte precursor cell. The method includes administering to the oligodendrocyte precursor cell an effective amount of a compound capable of promoting oligodendrocyte precursor cell differentiation. | 2012-07-05 |
| 20120172376 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS - The present invention relates to novel heterocyclic compounds of formula I | 2012-07-05 |
| 20120172377 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE - New heterocyclic compounds that may be used to modulate a histamine receptor in an individual are described. Pyrido[4,3-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 2012-07-05 |
